Axsome Therapeutics (AXSM) Announces Settlement Agreement Resolving AUVELITY Patent Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Axsome Therapeutics (AXSM) PT Raised to $190 at TD Cowen, Top Pick
February 11, 2025 5:25 AM ESTTD Cowen analyst Joseph Thome raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $190.00 (from $155.00) while maintaining a Buy rating.
The analyst comments "Axsome announced it has resolved Teva patent litigation related to Auvelity, which will allow entry of a generic... More
Axsome Therapeutics (AXSM) PT Raised to $167 at BofA Securities
February 10, 2025 10:40 AM ESTBofA Securities analyst Jason Gerberry raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $167.00 (from $143.00) while maintaining a Buy rating.
The analyst comments "This morning, Axsome announced a patent settlement pertaining to Auvelity key terms include a license for sole generic challenger (TEVA) to come to market in the 2038-39 time frame. Auvelity is an antidepressant that we... More
